论文部分内容阅读
目的探讨双抗和低分子肝素联合阿司匹林治疗急性脑梗死的临床疗效。方法 260例急性脑梗死患者,随机分为双抗组(150例)和联合组(110例)。双抗组给予氯吡格雷+阿司匹林治疗,联合组给予低分子肝素+阿司匹林治疗。比较两组临床疗效、NIHSS评分、凝血功能情况。结果双抗组总有效率为92.00%,联合组为91.82%,两组比较差异无统计学意义(P>0.05)。治疗前,两组NIHSS评分比较差异无统计学意义(P>0.05)。治疗后,两组NIHSS评分均明显降低,且组间比较差异无统计学意义(P>0.05)。治疗前,两组凝血酶原时间、血小板、纤维蛋白原差异无统计学意义(P>0.05)。治疗后,两组凝血酶原时间均明显升高,血小板及纤维蛋白原水平均显著降低,组间比较差异无统计学意义(P>0.05)。结论双抗和低分子肝素联合阿司匹林均能有效治疗急性脑梗死,安全性较高,值得临床推广应用。
Objective To investigate the clinical efficacy of double antibody and low molecular weight heparin combined with aspirin in the treatment of acute cerebral infarction. Methods 260 patients with acute cerebral infarction were randomly divided into double anti-group (150 cases) and combination group (110 cases). Double-resistant group was given clopidogrel + aspirin treatment, the combination group given low molecular weight heparin + aspirin treatment. The clinical efficacy, NIHSS score and coagulation status were compared between the two groups. Results The total effective rate of double-antibody group was 92.00% and that of combined group was 91.82%. There was no significant difference between the two groups (P> 0.05). Before treatment, there was no significant difference in NIHSS scores between the two groups (P> 0.05). After treatment, NIHSS scores of both groups were significantly lower, and there was no significant difference between the two groups (P> 0.05). Before treatment, prothrombin time, platelet, fibrinogen difference was not statistically significant (P> 0.05). After treatment, both prothrombin time were significantly increased, platelet and fibrinogen levels were significantly lower, there was no significant difference between the two groups (P> 0.05). Conclusion Both double-antibody and low-molecular-weight heparin combined with aspirin can effectively treat acute cerebral infarction, which is safe and worthy of clinical application.